Compare · BNTX vs RXRX
BNTX vs RXRX
Side-by-side comparison of BioNTech SE (BNTX) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.27B, about 11.1x RXRX ($2.00B).
- Over the past year, BNTX is down 14.2% and RXRX is down 34.7% - BNTX leads by 20.5 points.
- RXRX has been more active in the news (13 items in the past 4 weeks vs 11 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- BioNTech SE
- Recursion Pharmaceuticals Inc.
- Price
- $90.22+1.82%
- $4.15+11.11%
- Market cap
- $22.27B
- $2.00B
- 1M return
- -5.84%
- +30.30%
- 1Y return
- -14.25%
- -34.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 11
- 13
- Recent ratings
- 25
- 10
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
Latest RXRX
- SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.
- SEC Form 8-K filed by Recursion Pharmaceuticals Inc.
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
- Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
- SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.
- Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
- SEC Form 4 filed by Recursion Pharmaceuticals Inc.
- SEC Form 4 filed by Recursion Pharmaceuticals Inc.
- SEC Form 144 filed by Recursion Pharmaceuticals Inc.
- Director Dar Zavain was granted 4,607 shares, increasing direct ownership by 2% to 245,371 units (SEC Form 4)